EUVIMEDSkopri EUVIMED
MetaanalyseOpen access · CC BY 4.0

Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial

David Gunn iD, Rabia Topan, Lorna Barnard, Ron Fried, Ivana Holloway, Richard Brindle, Maura Corsetti iD, Mark Scott, Adam Farmer, Kapil Kapur, David Sanders, Maria Eugenicos and 10 more

Alimentary Pharmacology & Therapeutics · 2023-06 · 57 (11) · 1258-1271

DOI: 10.1111/apt.17426 ↗

At a glance

Metaanalyse in Alimentary Pharmacology & Therapeutics, published online on 2023-03-03. Written by David Gunn and 21 co-authors. Institution: NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK. Major MEDLINE topics: Irritable Bowel Syndrome. Cited 36 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Efficacy and Mechanism Evaluation Programme.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D).

Aim

To conduct a 12‐week parallel group, randomised, double‐blind, placebo‐controlled trial of ondansetron 4 mg o.d. (titrated up to 8 mg t.d.s.) in 400 IBS‐D patients. Primary endpoint: % responders using the Food and Drug Administration (FDA) composite endpoint. Secondary and mechanistic endpoints included stool consistency (Bristol Stool Form Scale) and whole gut transit time (WGTT). After literature review, results were pooled with other placebo‐controlled trials in a meta‐analysis to estimate relative risks (RR), 95% confidence intervals (CIs) and number needed to treat (NNT).

Results

Eighty patients were randomised. On intention‐to‐treat analysis, 15/37 (40.5%; 95% CI 24.7%–56.4%) met the primary endpoint on ondansetron versus 12/43 (27.9%; 95% CI 14.5%–41.3%) on placebo ( p = 0.19). Ondansetron improved stool consistency compared with placebo (adjusted mean difference − 0.7; 95% CI −1.0 to−0.3, p < 0.001). Ondansetron increased WGTT between baseline and week 12 (mean (SD) difference 3.8 (9.1) hours, versus placebo −2.2 (10.3) hours, p = 0.01). Meta‐analysis of 327 patients from this, and two similar trials, demonstrated ondansetron was superior to placebo for the FDA composite endpoint (RR of symptoms not responding = 0.86; 95% CI 0.75–0.98, NNT = 9) and stool response (RR = 0.65; 95% CI 0.52–0.82, NNT = 5), but not abdominal pain response (RR = 0.95; 95% CI 0.74–1.20).

Conclusions

Although small numbers meant the primary endpoint was not met in this trial, when pooled with other similar trials meta‐analysis suggests ondansetron improves stool consistency and reduces days with loose stool and urgency. Trial registration – http://www.isrctn.com/ISRCTN17508514

Subjects

MeSH terms (MEDLINE)

Irritable Bowel SyndromeHumansOndansetronDiarrheaDouble-Blind MethodFecesTreatment OutcomeRandomized Controlled Trials as Topic

Substances

Ondansetron

Authors and institutions

  • NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK.
  • Nottingham Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Barts and The London School of Medicine and Dentistry, London, UK.
  • Wingate Institute of Neurogastroenterology, Queen Mary University of London, London, UK.
  • Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Royal Stoke Hospital, University Hospitals of North Midlands NHS Trust, Stoke, UK.

ORCID profiles: David Gunn, Maura Corsetti, John Mclaughlin, Lesley Houghton, Alexander C Ford, Robin Spiller

Funding

  • Efficacy and Mechanism Evaluation Programme

Cite

APA

Gunn, D., Topan, R., Barnard, L., Fried, R., Holloway, I., Brindle, R., Corsetti, M., Scott, M., Farmer, A., Kapur, K., Sanders, D., Eugenicos, M., Trudgill, N., Whorwell, P., Mclaughlin, J., Akbar, A., Houghton, L., Dinning, P. G., Aziz, Q., …, & Spiller, R. (2023). Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology & Therapeutics, 57(11), 1258-1271. https://doi.org/10.1111/apt.17426

Vancouver

Gunn D, Topan R, Barnard L, Fried R, Holloway I, Brindle R, et al. Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial. Alimentary Pharmacology & Therapeutics. 2023;57(11):1258-1271. doi:10.1111/apt.17426

BibTeX
@article{Gunn2023,
  author = {Gunn, David and Topan, Rabia and Barnard, Lorna and Fried, Ron and Holloway, Ivana and Brindle, Richard and Corsetti, Maura and Scott, Mark and Farmer, Adam and Kapur, Kapil and Sanders, David and Eugenicos, Maria and Trudgill, Nigel and Whorwell, Peter and Mclaughlin, John and Akbar, Ayesha and Houghton, Lesley and Dinning, Phil G and Aziz, Qasim and Ford, Alexander C and Farrin, Amanda J and Spiller, Robin},
  title = {Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {11},
  pages = {1258--1271},
  doi = {10.1111/apt.17426}
}
Start for free →